Latest news

• Roche faces biosimilar blitz in 2018

  But Roche’s cancer antibody isn’t its only drug battling for market share - breast cancer blockbuster Herceptin (trastuzmab) also has a biosimilar rival in the form of Samsung Bioepis’Ontruzant,

• First Herceptin biosimilar cleared in Europe

  First Herceptin biosimilar cleared in Europe. Ontruzant is approved for all the same indications as Roche’s blockbuster. ... Ontruzant is the fourth biosimilar developed by the Korean company to receive marketing authorisation in the EU.

• CHMP backs maintenance therapy for Tesaro's Zejula

  The CHMP recommended approval of two biosimilars, namely Samsung Bioepis' Ontruzant (trastuzumab) - the first biosimilar of Roche's breast cancer therapy Herceptin to get a positive opinion in the EU - and

• Archive listing

  Ontruzant is set to be strong competition for Roche’s blockbuster. .